{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010269","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2025-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.310823+00:00","generated_at":"2026-05-24T18:00:19.673647+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NanoVibronix UroShield study shows 86% fewer UTIs, 70% fewer blockages, cost savings","bullets":["86% reduction in UTI incidence and 70% fewer catheter blockages in independent study published in Australian and New Zealand Continence Journal.","82.8% less bladder irrigations and 52.3% fewer catheter changes reported with UroShield use.","Resource costs reduced by 63.5% over 5 months, easing nursing workload and lowering healthcare expenses.","CEO Brian Murphy highlighted improved patient comfort and reduced catheter-related interventions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010269","json":"https://secwatch.observer/filing/0001493152-25-010269.json","markdown":"https://secwatch.observer/filing/0001493152-25-010269.md","text":"https://secwatch.observer/filing/0001493152-25-010269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225010269/0001493152-25-010269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225010269/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T18:00:19.673647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}